Navigation Links
L'OREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
Date:1/14/2010

PARIS and NORTH BRUNSWICK, N.J., Jan. 14 /PRNewswire/ -- L'OREAL and Hurel Corporation ("Hurel") today jointly announced that they have achieved the initial milestone of a research and development collaboration to create a new and transformational in vitro test for potential allergic reactions to substances that could come into contact with the skin.  The new device, named "Allergy Test on a Chip™," is intended to comprise a technological substitute for the animal test known as the local lymph node assay ("LLNA").  LLNA is presently accepted by regulatory agencies worldwide as a standard means for evaluating potential allergenic responses to new ingredients of consumer and industrial products.

"We are extremely pleased to partner with Hurel in the development of Allergy Test on a Chip, which is totally in line with our 25-year commitment in non-animal toxicology," said Jacques Leclaire, Ph.D., Director of Life Sciences Research at L'OREAL.  "Hurel's microdevice represents cutting-edge research and development, directed towards creating a breakthrough technology complementing our efforts in building alternative, integrated testing strategies.  While the ultimate success of this advanced and complex research project is not a certainty, the critical goal it addresses makes it a most worthwhile endeavor for us as a company."

R&D activities of the collaboration are being performed by Hurel in the United States, with contributions by L'OREAL's scientific team.  Allergy Test on a Chip, a patented embodiment of Hurel's multi-tissue, microfluidic cell culture technology, will integrate a reconstructed human skin; a separate cell culture capable of simulating a human immune system response (i.e., an allergic reaction); and means of microfluidically-mediated signaling between the skin construct where the allergenic stimulus originates and the immune system construct where the response to that stimulus occurs.  

In its recently completed first year, the collaboration achieved its initial milestone of demonstrating the microfluidic signaling component of the device.  In vivo, in response to an allergen contacting the skin, certain cells migrate out of the skin and into a nearby lymph node, where they signal the immune system to launch an allergic reaction.  Achieving the initial milestone entailed simulating this process of migration in a prototype microfluidic device.

"We are gratified to have achieved the initial milestone of our collaboration, and thrilled to play a key role as L'OREAL spearheads new, non-animal testing methods in the cosmetics industry," commented Robert Freedman, Chief Executive Officer of Hurel Corporation.  "Allergy Test on a Chip, if globally adopted, may dramatically reduce the use of animal tests in safety evaluation; and in part for this reason it has considerable commercial potential as well.  L'OREAL deserves tremendous credit for making the investments that will help create the toxicology of the twenty-first century.  Hurel takes the greatest pride in collaborating with a company of L'OREAL's global stature."

About L'OREAL

L'OREAL is the world leader in the cosmetics industry, developing innovative products to meet the diverse needs of customers in 130 countries worldwide.  Nearly 3,000 people work in the Group's 18 research centers, located in France, Asia and America.  Their findings are responsible for the registration of hundreds of patents annually.  

About Hurel Corporation

Hurel Corporation is the world leader in developing microfluidic, multi-tissue cell cultures and assay platforms which provide in vitro alternatives to animal testing while offering improved human-relevance of toxicological and metabolic prediction to scientists in the pharmaceutical, biotech, cosmetics, consumer products and industrial products industries.  More information is available at http://www.hurelcorp.com/

SOURCE Hurel Corporation

RELATED LINKS
http://www.hurelcorp.com

'/>"/>

SOURCE Hurel Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stryker Corporation Announces Pricing of Senior Notes
2. CVS Caremark Corporation Increases Quarterly Dividend 15%
3. Volcano Corporation Announces Preliminary Record Revenues for Fourth Quarter 2009; Total Year Revenues are Expected to Exceed Prior Guidance
4. Somanetics Corporation to Release Fourth Quarter and Fiscal 2009 Financial Results and Host Conference Call January 21, 2010
5. Colorado-Based Spectranetics Corporation to Pay $5 Million to Resolve Allegations Relating to its Medical Devices
6. Baxa Corporation to Sponsor Free Culture of Safety Webinar
7. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
8. Arrayit Corporation Announces Manufacturing Breakthrough
9. Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation
10. Vivakor Announces Launch of VivaThermic Website and Highlights Distribution & Sales of Its VivaThermic Products in Japan Through Veritas Corporation
11. Neogen Corporation Announces 2nd Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017   Science Exchange ... excited to announce that the first five replication ...  (RP:CB) have been published in eLife today. Despite ... represents the first practical evaluation of reproducibility rates ... reproducible studies. Unlike other assessments of reproducibility, the ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... similar agreements in Israel and Argentina ... 5 billion global market ... medical devices for the treatment of advanced wound care, announced today it signed ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST ...
(Date:1/19/2017)... The drug delivery technology market is projected ... 1,179.20 billion in 2016, at a CAGR of 7.2% ... diseases, increasing demand for biologics, technological advancements, and new ... this market. Whereas, self-administration & home care and rising ... opportunities for players operating in this market. On the ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... “The Land of More and More”: a brilliant story for children ... the simple and achievable answer. “The Land of More and More” is the creation ... in Angola, Indiana where he works with the children’s ministry department. , Michael ...
(Date:1/19/2017)... ... ... Today, the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians ... 2017. Clinicians who participate in APMs are paid for the quality of care they ... to build a system that delivers better care and one in which clinicians work ...
(Date:1/19/2017)... ... ... Next week after January 20th, the fear for many is that the humane ... of over 30 million. Many interviews with Dr. Carol Francis at the Los Angeles ... suppose to prioritize. Interviews provided below. , Among those present was Senator ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have to clear ... when clearing large amounts of snow, but they can be dangerous when used incorrectly. That’s ... Safety Commission for the proper use of snow blowers:, , When ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
Breaking Medicine News(10 mins):